Suppr超能文献

胰高血糖素样肽-1受体激动剂、双重GIP/GLP-1受体激动剂替尔泊肽与自杀意念及行为:临床研究与药物警戒报告的系统评价

Glucagon-Like Peptide-1 receptor agonists, dual GIP/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: A systematic review of clinical studies and pharmacovigilance reports.

作者信息

Di Stefano Ramona, Rindi Lorenzo V, Baldini Valentina, Rossi Rodolfo, Pacitti Francesca, Jannini Emmanuele A, Rossi Alessandro

机构信息

Department of Biotechnological and Applied Clinical Sciences, University of l'Aquila, L'Aquila, Italy; Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

出版信息

Diabetes Metab Syndr. 2025 Apr;19(4):103238. doi: 10.1016/j.dsx.2025.103238. Epub 2025 May 13.

Abstract

AIMS

Suicide is a global public health concern, accounting for nearly 700,000 deaths annually. Although well-established risk factors, including mental health disorders, are widely recognized, emerging concerns have surfaced regarding a potential association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual Gastric Inhibitory Polypeptide (GIP)/GLP-1 Receptor Agonist tirzepatide and suicidal behavior. This systematic review aims to synthesize the available evidence on the potential association between these drugs and suicidal behavior.

METHODS

This review was conducted following PRISMA guidelines. A systematic search was performed in MEDLINE, Embase, and APA PsycInfo up to September 24, 2024, using terms related to GLP-1 RAs/GIP/GLP-1 RAs and suicidal behavior.Three independent reviewers conducted article screening and data extraction. Risk of bias was evaluated using the Newcastle-Ottawa Scale for cohort studies and ROB2 for RCTs.

RESULTS

The review identified 16 studies published between 2017 and 2024, consisting of 5 observational studies, 2 randomized controlled trials, 8 pharmacovigilance analyses, and 1 post-hoc analysis of RCTs. No consistent evidence indicated an increased suicide risk among GLP-1 RA users. Pharmacovigilance analyses produced mixed findings; while some disproportionality analyses reported higher rates relative to other antihyperglycemic drugs, no causal link was confirmed. Cohort studies involving diabetic and obese populations generally did not demonstrate a significant increase in suicidal behavior.

CONCLUSIONS

Although current data do not warrant changes in prescribing practices, further research is needed before definitive conclusions can be drawn. Moreover, the generalizability and reliability of these findings should be interpreted in light of the methodological limitations of the included studies.

摘要

目的

自杀是一个全球公共卫生问题,每年导致近70万人死亡。尽管包括精神健康障碍在内的既定风险因素已得到广泛认可,但关于胰高血糖素样肽-1受体激动剂(GLP-1 RAs)、双重胃抑制多肽(GIP)/GLP-1受体激动剂替尔泊肽与自杀行为之间潜在关联的新担忧已经出现。本系统评价旨在综合现有证据,探讨这些药物与自杀行为之间的潜在关联。

方法

本评价遵循PRISMA指南进行。截至2024年9月24日,在MEDLINE、Embase和APA PsycInfo中进行了系统检索,使用了与GLP-1 RAs/GIP/GLP-1 RAs和自杀行为相关的术语。三位独立审阅者进行文章筛选和数据提取。使用纽卡斯尔-渥太华量表评估队列研究的偏倚风险,使用ROB2评估随机对照试验的偏倚风险。

结果

该评价纳入了2017年至2024年发表的16项研究,包括5项观察性研究、2项随机对照试验、8项药物警戒分析和1项随机对照试验的事后分析。没有一致的证据表明GLP-1 RA使用者的自杀风险增加。药物警戒分析结果不一;虽然一些不成比例分析报告相对于其他降糖药物的发生率较高,但未确认因果关系。涉及糖尿病和肥胖人群的队列研究一般未显示自杀行为显著增加。

结论

尽管目前的数据不支持改变处方习惯,但在得出明确结论之前还需要进一步研究。此外,这些发现的普遍性和可靠性应根据纳入研究的方法学局限性来解释。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验